Celgene Co. (NASDAQ:CELG)‘s stock had its “buy” rating reiterated by Cantor Fitzgerald in a report released on Tuesday.

A number of other equities analysts have also recently commented on the company. Leerink Swann upgraded Celgene from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $94.42 to $150.00 in a report on Friday, June 16th. They noted that the move was a valuation call. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and set a $98.00 price target (up from $93.00) on shares of Celgene in a research note on Wednesday, May 17th. William Blair reissued an “outperform” rating on shares of Celgene in a research note on Monday, June 26th. BTIG Research lowered Celgene from a “buy” rating to a “neutral” rating and raised their price target for the stock from $96.93 to $131.70 in a research note on Friday, June 30th. Finally, Canaccord Genuity set a $156.00 price target on Celgene and gave the stock a “buy” rating in a research note on Monday, May 22nd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Celgene currently has a consensus rating of “Buy” and a consensus target price of $147.44.

Celgene (NASDAQ:CELG) opened at 129.19 on Tuesday. The firm’s 50-day moving average is $133.54 and its 200 day moving average is $125.26. Celgene has a 12-month low of $96.93 and a 12-month high of $139.00. The company has a market cap of $101.07 billion, a price-to-earnings ratio of 40.01 and a beta of 1.89.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. Celgene had a return on equity of 52.90% and a net margin of 32.47%. The company’s quarterly revenue was up 18.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.44 EPS. On average, equities analysts expect that Celgene will post $7.32 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Celgene Co. (CELG) Rating Reiterated by Cantor Fitzgerald” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/24/celgene-co-celg-rating-reiterated-by-cantor-fitzgerald.html.

In related news, Director Michael D. Casey sold 9,250 shares of the business’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the transaction, the insider now owns 4,004 shares in the company, valued at $481,200.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 253,761 shares of company stock worth $33,792,445. 0.95% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in CELG. Capital Counsel LLC NY increased its stake in Celgene by 0.4% in the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 6 shares during the last quarter. Diversified Trust Co increased its stake in Celgene by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 9 shares during the last quarter. Fort Pitt Capital Group LLC increased its stake in Celgene by 0.6% in the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after buying an additional 11 shares during the last quarter. Sowell Financial Services LLC increased its stake in Celgene by 0.5% in the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 13 shares during the last quarter. Finally, South Texas Money Management Ltd. increased its stake in Celgene by 0.6% in the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 78.34% of the company’s stock.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related stocks with our FREE daily email newsletter.